BRAF突变与手术治疗的转移性结直肠癌肝切除后生存与复发的关系
这项多中心回顾性队列研究纳入849例接受治愈性肝切除的结直肠癌肝转移患者,评估BRAF V600E与非V600E突变与无病生存(DFS)和总生存(OS)的关联。多因素分析显示,V600E突变(而非非V600E突变)与更差的OS(HR 2.76,95%CI 1.74-4.37,P<.001)和DFS(HR 2.04,95%CI 1.30-3.20,P=.002)独立相关,且其预后关联强度超过KRAS突变。
要点
- V600E BRAF突变与肝切除后更差OS和DFS独立相关。
- 非V600E BRAF突变未显示与OS或DFS的显著关联。
- V600E BRAF突变的预后关联强度超过KRAS突变。
核心结论
- V600E BRAF突变与手术治疗结直肠癌肝转移患者更差预后和更高复发风险相关。
- V600E突变不仅是比KRAS更强的预后因素,也是整个队列中最强的预后决定因素。
研究设计与样本
- 国际结直肠癌肝转移遗传学联盟参与机构的回顾性队列研究。
- 纳入2000年1月1日至2016年12月31日期间接受治愈性肝切除且有BRAF和KRAS突变数据的结直肠癌肝转移患者。
- 853例符合纳入标准,849例纳入分析;男性510例(59.8%),女性343例(40.2%),平均年龄60.2(SD 12.4)岁。
- 采用多因素Cox比例风险回归模型评估长期结局。
主要发现
- 43例(5.1%)为mutBRAF/wtKRAS基因型,480例(56.5%)为wtBRAF/wtKRAS,326例(38.4%)为wtBRAF/mutKRAS。
- 与wtBRAF/wtKRAS组相比,mutBRAF/wtKRAS组更多为女性(27例[62.8%] vs 169例[35.2%])、65岁及以上(22例[51.2%] vs 176例[36.9%])、右半原发肿瘤(27例[62.8%] vs 83例[17.4%])和异时性肝转移(28例[64.3%] vs 229例[46.8%])。
- 多因素分析中,V600E BRAF突变与更差OS相关(HR 2.76;95%CI 1.74-4.37;P<.001),非V600E突变无显著关联。
- V600E BRAF突变与更差DFS相关(HR 2.04;95%CI 1.30-3.20;P=.002)。
- V600E BRAF突变对OS和DFS的关联强于KRAS突变(OS的β值10.15 vs 2.94;DFS的β值7.14 vs 2.27)。
临床怎么用
- 对结直肠癌肝转移行肝切除患者,可检测BRAF V600E突变以辅助预后分层。
- V600E突变提示复发和死亡风险较高,可能需更密切随访。
局限性
- 回顾性队列研究设计。
- 仅纳入有BRAF和KRAS突变数据的患者,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: BRAF mutations are reportedly associated with aggressive tumor biology. However, in contrast with primary colorectal cancer, the association of V600E and non-V600E BRAF mutations with survival and recurrence after resection of colorectal liver metastases (CRLM) has not been well studied. OBJECTIVE: To investigate the prognostic association of BRAF mutations with survival and recurrence independently and compared with other prognostic determinants, such as KRAS mutations. DESIGN, SETTING, AND PARTICIPANTS: In this cohort study, all patients who underwent resection for CRLM with curative intent from January 1, 2000, through December 31, 2016, at the institutions participating in the International Genetic Consortium for Colorectal Liver Metastasis and had data on BRAF and KRAS mutational status were retrospectively identified. Multivariate Cox proportional hazards regression models were used to assess long-term outcomes. INTERVENTIONS: Hepatectomy in patients with CRLM. MAIN OUTCOMES AND MEASURES: The association of V600E and non-V600E BRAF mutations with disease-free survival (DFS) and overall survival (OS). RESULTS: Of 853 patients who met inclusion criteria (510 men [59.8%] and 343 women [40.2%]; mean [SD] age, 60.2 [12.4] years), 849 were included in the study analyses. Forty-three (5.1%) had a mutated (mut) BRAF/wild-type (wt) KRAS (V600E and non-V600E) genotype; 480 (56.5%), a wtBRAF/wtKRAS genotype; and 326 (38.4%), a wtBRAF/mutKRAS genotype. Compared with the wtBRAF/wtKRAS genotype group, patients with a mutBRAF/wtKRAS genotype more frequently were female (27 [62.8%] vs 169 [35.2%]) and 65 years or older (22 [51.2%] vs 176 [36.9%]), had right-sided primary tumors (27 [62.8%] vs 83 [17.4%]), and presented with a metachronous liver metastasis (28 [64.3%] vs 229 [46.8%]). On multivariable analysis, V600E but not non-V600E BRAF mutation was associated with worse OS (hazard ratio [HR], 2.76; 95% CI, 1.74-4.37; P < .001) and DFS (HR, 2.04; 95% CI, 1.30-3.20; P = .002). The V600E BRAF mutation had a stronger association with OS and DFS than the KRAS mutations (β for OS, 10.15 vs 2.94; β for DFS, 7.14 vs 2.27). CONCLUSIONS AND RELEVANCE: The presence of the V600E BRAF mutation was associated with worse prognosis and increased risk of recurrence. The V600E mutation was not only a stronger prognostic factor than KRAS but also was the strongest prognostic determinant in the overall cohort.
引用
- Margonis GA, Buettner S, Andreatos N, et al. Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer. JAMA Surg. 2018. PMID: 29799910. doi:10.1001/jamasurg.2018.0996
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。